Clinical trial

Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

NCT00765947

Drugs and interventions used in this trial

3 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Aliskiren Normalized identity: aliskirenView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Hydrochlorothiazide Normalized identity: hydrochlorothiazideView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Amlodipine Normalized identity: amlodipineView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Efficacy and Tolerability of an Aliskiren-based Treatment Algorithm in Patients With Mild to Moderate Hypertension

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-09-01

PhasePHASE4

Conditions

Essential Hypertension ( Mild to Moderate)unresolved

Interventions

AliskirenDRUG · verified · RxNorm: aliskiren

HydrochlorothiazideDRUG · verified · RxNorm: hydrochlorothiazide

AmlodipineDRUG · verified · RxNorm: amlodipine

Sponsors & collaborators

Novartislead sponsor

Mapped research locations

ParisFrance1 BudapestHungary1 BucharestRomania1 BratislavaSlovakia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00765947 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.